Relevance and irrelevance of DNA damage response to radiotherapy

被引:27
作者
Connell, PP
Kron, SJ
Weichselbaum, RR
机构
[1] Univ Chicago, Ctr Mol Oncol, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA
[2] Univ Chicago, Ctr Mol Oncol, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA
基金
美国国家卫生研究院;
关键词
ionizing radiation; DNA; tumors;
D O I
10.1016/j.dnarep.2004.04.004
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Ionizing radiation (IR) has been used to treat human malignancies since the early part of the 20th century. To date, most of the advances in radiotherapy have focused on optimization of treatment delivery schedules and technologic improvements in the physical targeting of dose. By comparison, many of the discoveries regarding the molecular basis of DNA damage and repair have not yet been translated to clinical practice. This article offers some perspectives regarding modulators of radiation effects and the challenges faced as we approach newer molecular targets. Our goal is to frame the issues that contribute to the apparent disconnect between laboratory discoveries and improvements in clinically relevant therapeutics. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:1245 / 1251
页数:7
相关论文
共 62 条
  • [1] Belenkov AI, 2002, CANCER RES, V62, P5888
  • [2] Does amifostine have a role in chemoradiation treatment?
    Brizel, DM
    [J]. LANCET ONCOLOGY, 2003, 4 (06) : 378 - 381
  • [3] Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer
    Brizel, DM
    Albers, ME
    Fisher, SR
    Scher, RL
    Richtsmeier, WJ
    Hars, V
    George, SL
    Huang, AT
    Prosnitz, LR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (25) : 1798 - 1804
  • [4] Phase III randomized trial of amifostine as a radioprotector in head and neck cancer
    Brizel, DM
    Wasserman, TH
    Henke, M
    Strnad, V
    Rudat, V
    Monnier, A
    Eschwege, F
    Zhang, J
    Russell, L
    Oster, W
    Sauer, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (19) : 3339 - 3345
  • [5] BUSH RS, 1978, BRIT J CANCER, V37, P302
  • [6] Collis SJ, 2003, CANCER RES, V63, P1550
  • [7] Ribozyme minigene-mediated RAD51 down-regulation increases radiosensitivity of human prostate cancer cells
    Collis, SJ
    Tighe, A
    Scott, SD
    Roberts, SA
    Hendry, JH
    Margison, GP
    [J]. NUCLEIC ACIDS RESEARCH, 2001, 29 (07) : 1534 - 1538
  • [8] A hot spot for RAD51C interactions revealed by a peptide that sensitizes cells to cisplatin
    Connell, PP
    Siddiqui, N
    Hoffman, S
    Kuang, A
    Khatipov, EA
    Weichselbaum, RR
    Bishop, DK
    [J]. CANCER RESEARCH, 2004, 64 (09) : 3002 - 3005
  • [9] TOLERANCE OF NORMAL TISSUE TO THERAPEUTIC IRRADIATION
    EMAMI, B
    LYMAN, J
    BROWN, A
    COIA, L
    GOITEIN, M
    MUNZENRIDER, JE
    SHANK, B
    SOLIN, LJ
    WESSON, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (01): : 109 - 122
  • [10] Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study
    Flam, M
    John, M
    Pajak, TF
    Petrelli, N
    Myerson, R
    Doggett, S
    Quivey, J
    Rotman, M
    Kerman, H
    Coia, L
    Murray, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (09) : 2527 - 2539